Table 1.
Pathologies and biomarkers.
| Pathology | Biomarker Found | Control (N) | Participants (N) | Reference |
|---|---|---|---|---|
| PD | 8-OHdG, MDA, nitrite, ferritin | 6037 | MA. 80 studies, N = 7212 | [21] |
| CVD | 8-OHdG OxLDL |
1106 1727 |
MA. 14 studies, N = 810 prospective population-based case–cohort study, N = 333 |
[22,23] |
| Cancer, solid tumors | 8-OHdG, γH2AX | MA. 21 studies, N = 2121 | [24,25] | |
| COPD | MDA | 530 | MA. 14 studies, N = 817 | [26] |
| AMD | MDA | 656 | MA. 12 studies, N = 634 | [27] |
| Aging | PCOOH | Young, 20 | Aged 20 | [28] |
| Atherosclerosis | oxLDL | MA. 12 studies, N = 8644 | [29] | |
| DM | AOPPs, MDA |
30 30 |
DM patients 24 75 |
[30,31,32] |
| Alzheimer’s disease | HO-1, 8-OHdG, HNE, isoprostanes, PCO, nitrotyrosine, AGEs |
Review, 97 published articles | [33] |
The main pathologies that are linked to the specific biomarkers of OS based on the citations above and a review recently published about the biomarkers measuring inflammation and OS. (MA. = meta-analysis ; N = number of participants). Abbreviations see below.